Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ: PACB) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT (1:30 PM ET) in San Francisco.
A live webcast will be available on the company investor site and a replay will be posted for at least 30 days after the event.
PacBio (NASDAQ: PACB) said management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 11:30 AM ET in New York.
A live webcast will be available on the company investor site at investor.pacificbiosciences.com, with a replay accessible for at least 30 days after the event.
PacBio (NASDAQ: PACB) announced management will participate in three investor conferences the week of November 18–19, 2025: Wolfe Research Healthcare Conference in New York, Jefferies Global Healthcare Conference in London, and Stephens Annual Investment Conference in Nashville.
Scheduled events include fireside chats on Nov 18 at 8:40 AM ET (Wolfe) and Nov 19 at 10:00 AM CT (Stephens); Jefferies meetings will be 1x1 sessions on Nov 19. Live webcasts of the fireside chats will be available at the company investor site, with replays available for at least 30 days.
PacBio (NASDAQ: PACB) reported Q3 2025 results for the quarter ended September 30, 2025. Revenue was $38.4M versus $40.0M a year ago; instrument revenue fell to $11.3M while consumables rose to $21.3M. GAAP gross profit was $15.9M and non-GAAP gross margin improved to 42% from 33% a year earlier. Non-GAAP operating expenses were $53.9M versus $62.4M in Q3 2024. Non-GAAP net loss narrowed to $36.8M (non-GAAP EPS $0.12). Cash and investments totaled $298.7M.
Product and program updates include the new SPRQ-Nx chemistry (targeting up to 40% sequencing cost reduction), Class III device registration in China for Sequel II CNDx, expanded PureTarget assays, and Revio selections for major genomics projects.
PacBio (NASDAQ: PACB) announced a multi-center preprint from the HiFi Solves EMEA Consortium showing that HiFi sequencing with Paraphase detected 100% of 125 known pathogenic variants in 86 individuals across 11 complex genomic regions.
The study used one SMRT Cell per sample with a median read length of 15.5 kb and mean per-base accuracy above 99.9%, demonstrating phasing, copy-number resolution, and detection of complex events (gene conversions) in paralogous regions previously inaccessible to short reads.
The consortium now spans 23 institutions in 16 countries, and authors say results support broader clinical adoption of high-accuracy long-read genomes for rare disease and diagnostic testing.
PacBio (NASDAQ: PACB) said the Sequel II CNDx system gained NMPA Class III medical device approval in China through its partner Berry Genomics on Nov 4, 2025.
This marks the first regulatory clearance of a clinical-grade long-read sequencer worldwide and enables Berry to offer an end-to-end long-read HiFi sequencing workflow in China, initially targeting thalassemia carrier, prenatal, newborn, and rare-disease testing. The system delivers long reads (≥20 kb) with high accuracy, detecting SNVs, indels, CNVs, SVs, repeat expansions and enabling phasing in a single run. PacBio and Berry plan to expand clinical assays and support deployment with AI analysis and local partnerships to reduce turnaround times and increase diagnostic yield.
PacBio (NASDAQ: PACB) will report third quarter 2025 financial results and host a conference call on Wednesday, November 5, 2025 at 4:30 PM ET (1:30 PM PT). The call will be webcast and available at https://investor.pacificbiosciences.com/.
Listen live via internet or by phone: toll-free 1-888-349-0136 or international 1-412-317-0459. Dial-in participants should join 10 minutes early and request to join the "PacBio Q3 Earnings Call".
PacBio (NASDAQ: PACB) announced SPRQ-Nx chemistry and consumables for Revio and Vega to reduce HiFi genome sequencing costs and add multiomic and regulated‑lab features. PacBio says customers at scale could see up to a 40% cost reduction, bringing per‑genome costs to under $300, with beta testing on Revio beginning November 2025 and commercial availability in 2026. Beta participants can purchase 384 genomes of reagents at about $250 per genome.
Other upgrades include 5hmC epigenetic detection, faster Vega runs (2–4 hours), 21 CFR Part 11 authentication and audit logging, and long‑term support for Revio and Vega through 2032.
PacBio (NASDAQ:PACB) announced on October 13, 2025 that its HiFi sequencing technology was selected as the primary platform for the Korean Pangenome Reference Project led by KDCA/KNIH.
The program aims to generate >1,000 telomere-to-telomere quality reference genomes representing the Korean population, integrate data into the global Human Pangenome Reference Consortium, and accelerate discovery of population-specific variants to support precision diagnostics, therapeutics, and disease research.
PacBio will provide HiFi whole-genome sequencing, full-length RNA analysis, and chromosome-scale CiFi technology as an integrated solution.
PacBio (NASDAQ: PACB) will sequence up to 7,800 whole genomes and epigenomes from the National Institute on Aging's Long Life Family Study using its Revio system and HiFi long‑read, methylation‑aware protocols. The program begins in Q4 2025 at the McDonnell Genome Institute with an initial tranche of ~5,500 samples and is planned to span five years. The LLFS renewal includes $80 million in NIA funding (2U19AG063893-06) for sequencing and recruitment. Goals include detecting structural variants, methylation signatures, and integrating genomics with longitudinal phenotypes to study exceptional longevity.